Amplification of Telomerase (hTERT) Gene is a Poor Prognostic Marker in Non-small-cell Lung Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Apr 28

PMID 16641908

Citations 49

Authors

C-Q Zhu

J-C Cutz

N Liu

D Lau

F A Shepherd

J A Squire

M-S Tsao

Affiliations

Soon will be listed here.

Abstract

Telomerase reactivation is a hallmark of human carcinogenesis. Increased telomerase activity may result from gene amplification and/or overexpression. This study evaluates the prognostic value of hTERT gene amplification and mRNA overexpression in 144 resectable non-small-cell lung cancer (NSCLC) specimens. The hTERT gene copy number was assessed by quantitative polymerase chain reaction (qPCR) on laser-capture microdissected tumour cells of 81 tumours, and by fluorescence in situ hybridisation (FISH) on a subset of 59 tumours. hTERT mRNA level was determined by reverse transcription (RT)-qPCR in 130 tumours. In total, 57% of (46 out of 81) primary NSCLC specimens demonstrated hTERT amplification, which was significantly more common (P<0.001) in adenocarcinoma (30 out of 40) than in squamous cell carcinoma (13 out of 37). The hTERT mRNA overexpression was noted in 74% (94 out of 130) of tumours; it was more frequent in squamous cell than in adenocarcinoma (87 vs 68%, P=0.03). Overexpression was significantly associated with amplification (P=0.03), especially in adenocarcinoma. The hTERT gene amplification was prognostic for shorter recurrence-free survival (hazard ratio=2.16, P=0.03). These data indicate that gene amplification is an important mechanism for hTERT overexpression in lung adenocarcinoma and is an independent poor prognostic marker for disease-free survival in NSCLC.

Citing Articles

Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.

Chen Z, Vallega K, Wang D, Quan Z, Fan S, Wang Q J Exp Med. 2024; 221(11).

PMID: 39297884 PMC: 11413468. DOI: 10.1084/jem.20240435.

Clinical and molecular correlates of tumor aneuploidy in metastatic non-small cell lung cancer.

Spurr L, Pitroda S Sci Rep. 2024; 14(1):19375.

PMID: 39169079 PMC: 11339421. DOI: 10.1038/s41598-024-66062-5.

Two co-inherited SNPs of the telomerase reverse transcriptase (TERT) gene are associated with Iraqi patients with lung cancer.

Lawi Z, Alkhammas A, Elerouri M, Ben A, Al-Shuhaib M J Med Biochem. 2023; 42(4):694-705.

PMID: 38084250 PMC: 10710799. DOI: 10.5937/jomb0-41553.

Assessment of MYC and TERT copy number variations in lung cancer using digital PCR.

Brik A, Wichert K, Weber D, Szafranski K, Rozynek P, Meier S BMC Res Notes. 2023; 16(1):279.

PMID: 37858127 PMC: 10585721. DOI: 10.1186/s13104-023-06566-x.

TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities.

Kuhn C, Meister J, Kreft S, Stiller M, Puppel S, Zaremba A PLoS One. 2023; 18(7):e0281487.

PMID: 37418389 PMC: 10328343. DOI: 10.1371/journal.pone.0281487.

References

Toomey D, Smyth G, Condron C, Kay E, Conroy R, Foley D . Immune function, telomerase, and angiogenesis in patients with primary, operable nonsmall cell lung carcinoma: tumor size and lymph node status remain the most important prognostic features. Cancer. 2001; 92(10):2648-57. DOI: 10.1002/1097-0142(20011115)92:10<2648::aid-cncr1618>3.0.co;2-7. View

Lantuejoul S, Soria J, Moro-Sibilot D, Morat L, Veyrenc S, Lorimier P . Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer. 2004; 90(6):1222-9. PMC: 2410220. DOI: 10.1038/sj.bjc.6601643. View

Shay J, Roninson I . Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene. 2004; 23(16):2919-33. DOI: 10.1038/sj.onc.1207518. View

Zhang A, Zheng C, Hou M, Lindvall C, Wallin K, Angstrom T . Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas. Genes Chromosomes Cancer. 2002; 34(3):269-75. DOI: 10.1002/gcc.10071. View

Bieche I, Nogues C, Paradis V, Olivi M, Bedossa P, Lidereau R . Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res. 2000; 6(2):452-9. View

Tsao M, Liu N, Chen J, Pappas J, Ho J, To C . Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer. 1998; 20(1):1-16. DOI: 10.1016/s0169-5002(98)00007-5. View

Fujiwara M, Kamma H, Wu W, Hamasaki M, Kaneko S, Horiguchi H . Expression and alternative splicing pattern of human telomerase reverse transcriptase in human lung cancer cells. Int J Oncol. 2004; 24(4):925-30. View

Kang S, Kwon T, Kwon D, Do S . Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem. 1999; 274(19):13085-90. DOI: 10.1074/jbc.274.19.13085. View

Wu T, Lin P, Hsu C, Huang Y, Chen C, Chung W . Loss of telomerase activity may be a potential favorable prognostic marker in lung carcinomas. Lung Cancer. 2003; 41(2):163-9. DOI: 10.1016/s0169-5002(03)00195-8. View

10.

Zhu C, Blackhall F, Pintilie M, Iyengar P, Liu N, Ho J . Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker. Clin Cancer Res. 2004; 10(6):1984-91. DOI: 10.1158/1078-0432.ccr-03-0470. View

11.

Kolquist K, Ellisen L, Counter C, Meyerson M, Tan L, Weinberg R . Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998; 19(2):182-6. DOI: 10.1038/554. View

12.

Hara H, Yamashita K, Shinada J, Yoshimura H, Kameya T . Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer. Lung Cancer. 2001; 34(2):219-26. DOI: 10.1016/s0169-5002(01)00244-6. View

13.

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C . Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 352(25):2589-97. DOI: 10.1056/NEJMoa043623. View

14.

Fan X, Wang Y, Kratz J, Brat D, Robitaille Y, Moghrabi A . hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol. 2003; 162(6):1763-9. PMC: 1868122. DOI: 10.1016/S0002-9440(10)64311-8. View

15.

Wang L, Soria J, Kemp B, Liu D, Mao L, Khuri F . hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res. 2002; 8(9):2883-9. View

16.

Komiya T, Kawase I, Nitta T, Yasumitsu T, Kikui M, Fukuoka M . Prognostic significance of hTERT expression in non-small cell lung cancer. Int J Oncol. 2000; 16(6):1173-7. DOI: 10.3892/ijo.16.6.1173. View

17.

Massion P, Kuo W, Stokoe D, Olshen A, Treseler P, Chin K . Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 2002; 62(13):3636-40. View

18.

Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W . High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst. 1997; 89(21):1609-15. DOI: 10.1093/jnci/89.21.1609. View

19.

Murnane J, Sabatier L . Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. Bioessays. 2004; 26(11):1164-74. DOI: 10.1002/bies.20125. View

20.

Lu C, Soria J, Tang X, Xu X, Wang L, Mao L . Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol. 2004; 22(22):4575-83. DOI: 10.1200/JCO.2004.01.091. View